110 results about "Low dose" patented technology

The invention relates to a double-cavity radiotherapy and chemotherapy integrated treatment capsule for brain glioma, which aims to solve the problems that the existing radioactive seed source or chemotherapy carrier cannot give consideration to radiotherapy and chemotherapy, the dosage is difficult to regulate and control, the medicine distribution is non-uniform and the like. The brain glioma double-cavity radiotherapy and chemotherapy integrated treatment bag is composed of a radiotherapy pipeline and a chemotherapy pipeline, the whole integrated treatment bag is a spiral pipe body, the radiotherapy pipeline is located in an inner ring, the chemotherapy pipeline is located in an outer ring, the radiotherapy pipeline is a closed cavity, a liquid radioactive source is contained in the closed cavity, and the liquid radioactive source is located in an outer ring. The chemotherapy medicine is released from the head end of the chemotherapy pipeline, the chemotherapy medicine is injected from the tail end of the chemotherapy pipeline, and the surface of the integrated treatment bag is coated with a composite antibacterial layer. According to the integrated treatment capsule, radiopharmaceuticals and chemical drugs are placed in the inner cavity and the outer cavity respectively, synergistic treatment of radiotherapy and chemotherapy is achieved through the synchronous effect of the two channels, and long-term low-dose release of the radiopharmaceuticals and the chemotherapy drugs is achieved and toxic and side effects are reduced by adjusting the screw pitch and the thickness of the tube wall.

The invention provides a low-dose CT image processing method and device, electronic equipment and a medium, and relates to the field of medical image processing, and the method comprises the steps: obtaining a to-be-processed low-dose CT image; performing noise characteristic quantization on the low-dose CT image to generate noise characteristics; extracting image features of the low-dose CT image by adopting a trained image processing model, fusing the image features with the noise features to obtain fused features, and processing the fused features to obtain a target CT image; according to the method, accurate denoising of the low-dose CT image can be realized, diagnosis details such as organ boundaries and blood vessels are efficiently reserved, the robustness of the model to various noise scenes is enhanced, the calculation overhead is reduced, and a high-quality target CT image meeting clinical diagnosis requirements is output.

A method, system, and device for ultra-low-dose imaging of oral cone-beam computed tomography (CBCT) are provided. The method encompasses high-dose oral CBCT image data acquisition, data segmentation processing, three-dimensional (3D) reconstruction processing, model training, image data input, image enhancement, and image data output. Specifically, the process involves performing 3D reconstruction on 2D projection data of oral CBCT acquired in ultra-low-dose mode to obtain ultra-low-dose oral CBCT 3D reconstructed image data. This ultra-low-dose oral CBCT 3D reconstructed image data is then input into the oral CBCT ultra-low-dose imaging enhancement network model, from which high-quality oral CBCT image data is output for subsequent clinical diagnosis and treatment processes. This method significantly reduces the radiation dose of imaging while ensuring imaging quality, accelerates imaging speed, and enhances the safety of oral CBCT imaging, holding broad clinical application prospects.

This invention discloses a method for detecting the toxicity threshold of a substance based on a rat drinking experiment. The method of this invention includes the following steps: First, a drinking preference experiment is conducted, and then the toxicity threshold is determined: the amount of substance water and pure water consumed in the drinking preference is compared to determine the time when the rat begins to significantly avoid substance water, the mass of the toxic substance in the rat's body at that time is calculated, and the toxicity threshold of the rat is calculated; (3) dose conversion from rat to human: based on the interspecies dose conversion of body surface area, the toxicity threshold of the rat is first converted into the equivalent dose for humans to obtain the acute exposure dose, and then the acute exposure dose is converted into the chronic exposure dose for humans to obtain the substance toxicity threshold. This invention can accurately determine the toxicity threshold: it achieves toxicity assessment of low-dose exposure through spontaneous recognition behavior; it is easy to operate; and it is applicable to the toxicity assessment and non-destructive threshold determination of various substances such as environmental pollutants, chemical substances, and drugs.

State of the art mechanisms being used for achieving diagnostic-quality images under low-dose settings for general CT imaging have the disadvantages that CT images are fixed during the optimization process to generate perfusion maps, which can lead to suboptimal CT images with respect to the perfusion maps generated, although they might appear spatially smooth or denoised. The disclosure herein generally relates to Computer Tomography (CT) scanning, and, more particularly, to a method and system for CT image reconstruction. The system performs modelling an optimization problem for joint estimation of a set of structural CT images and a perfusion map, and further solves the optimization problem for the reconstruction of the CT images of a subject.

The present disclosure provides an IL-6 formulation, comprising about 40 μg / mL to about 2 mg / ml IL-6, about 5 to about 15 mM histidine, about 5 to about 15 mg / mL glycine, about 40 to about 60 mg / mL trehalose, about 0.1 to about 0.3 mg / mL polysorbate 20, and about 1 to about 1000 μM DTPA, wherein the formulation has a pH of about 6.0 to about 8.0. Such formulations may be useful to treat and / or prevent a disease or disorder in a subject in need thereof.

The invention relates to a low-dose liquid-free detection system, which is used for a net type atomizer and comprises an acquisition unit, an analysis unit, a calculation unit, a data storage unit and an execution unit, the acquisition unit is used for acquiring current or voltage signals of an atomizing sheet in one or more periods and sending the current or voltage signals to the calculation unit; the calculation unit is used for acquiring the current or voltage signal sent by the acquisition unit, obtaining a change fitting curve of the current or voltage signal through differential operation, and sending data of the change fitting curve to the analysis unit; and the analysis unit is used for receiving the change fitting curve data sent by the calculation unit, comparing the change fitting curve data with the pre-stored threshold data of the atomization sheet in the data storage unit, carrying out final judgment on a liquid medicine atomization state or a non-liquid medicine atomization state, and sending a judgment result to the execution unit. The liquid-free detection system is suitable for low-dose atomization detection.

A computer-implemented method for determining scar segmentation includes receiving a medical image of an object to be segmented acquired after an application of a low-dose of contrast agent and determining a scar segmentation mask by applying a trained artificial neural network to the medical image. The low-dose of the contrast agent includes less contrast-agent than a standard full-dose of the contrast agent.

Embodiments provide targeted delivery of powder medications (high and low dose) within the nose and to different nasal regions. Oscillating jet technology provides a unique approach to minimize hotspot formation and the associated irritation associated with high powder mass applications together with improved posterior surface area coverage and improved drug absorption for locally acting or systemically and neurologically targeted medications.

The present disclosure provides a method of administering a low dose soluble protein to a subject in need thereof, wherein the method comprises (a) adding an intravenous solution stabilizer ("IVSS") to an isotonic aqueous solution in a container to form a pretreated container, (b) adding an amount from a protein stock solution to the pretreated container of step (a) to form a low dose protein solution, and (c) administering the low dose protein solution of step (b) to the subject. Optionally, the dose of the soluble protein to be administered to the subject is an ultra-low dose protein, wherein the low dose protein solution undergoes a further dilution step. In particular, the method of administering an ultra-low dose soluble protein comprises: (a) adding an IVSS to an isotonic aqueous solution in a first container to form a first pretreated container, (b) adding an amount from the protein stock solution to the first pretreated container to form a low dose protein solution; (c) adding an IVSS to an isotonic aqueous solution in a second container to form a second pretreated container; and (d) adding an amount of the low dose protein solution in step (b) to the second pretreated container of step (c) to form an ultra-low dose protein solution, and (e) administering the low dose protein solution of step (b) to an individual in need thereof.

The invention belongs to the field of X-ray long-afterglow luminescent materials. The technical problems that traditional Pr < 3 + > doped fluoride is insufficient in afterglow performance, X-ray imaging depends on continuous irradiation, and color scattering noisy points exist are solved. The NaLuF4: Mg / Cs / Pr fluoride material is prepared by adopting a Cs < + >-Mg < 2 + > co-doping regulation strategy, the material is synthesized by an oleic acid-octadecene liquid phase method, and the X-ray excitation afterglow intensity of Pr < 3 + > is improved by about 110 times by utilizing the synergistic effect that Cs < + > enhances X-ray absorption and Mg < 2 + > optimizes a carrier shallow-deep trap level; the material is prepared into the high-light-transmittance rare earth nano flexible scintillation screen with the resolution ratio of 20.01 lp / mm. According to the invention, zero-noisy-point time-delay imaging after low-dose X-ray transient irradiation is realized, continuous irradiation is not needed, the radiation dose is lower, and the method is mainly applied to the field of X-ray time-delay imaging of low-dose medical diagnosis and industrial nondestructive testing. The method does not need continuous X-ray irradiation, and has important application value in the fields of medical diagnosis, industrial nondestructive testing and the like.

The present invention is directed to a method of treating acute ischemic stroke in a human comprising administering one of more low doses of DC009, wherein the dose is about 0.01-0.075 mg / kg / dose. The low dose administration is safe and effective in treating acute ischemic stroke in a human subject.

The invention discloses a process for synergistically inhibiting melanoma by carrying low-dose paclitaxel on nanoparticles based on immunoregulation. According to the invention, hyaluronic acid functionalized albumin nanoparticles are combined with low-dose paclitaxel, the tumor targeting property of the drug is improved by utilizing a nanotechnology, and meanwhile, the tumor immune microenvironment is regulated and the anti-tumor immune effect is enhanced by activating an STING pathway. Through the combination, the treatment effect of the medicine is improved, the side effect of the medicine is remarkably reduced, and a new strategy is provided for tumor treatment. High-efficiency delivery of low-dose paclitaxel is realized through the nano-carrier, the drug dosage is reduced, the toxicity is reduced, meanwhile, the antitumor activity of the paclitaxel is retained, a new thought is provided for clinical application of traditional chemotherapeutic drugs, the tolerance and life quality of patients are expected to be improved, polarization of M1 type macrophages is promoted by activating an STING pathway, and the antitumor activity of the paclitaxel is improved. Interferon and other inflammatory factors are released, CD8 + T cells are recruited and activated, and therefore the anti-tumor effect is achieved.

A treatment for patients having cancer expressing Prostate Cancer Specific Membrane Antigen (PSMA) is disclosed. Said treatment involves the use of an 225Ac-radioconjugate, in particular 225Ac-PSMA-I&T. A dosage regimen that entails more frequent administration of the 225Ac-radioconjugate at lower dose level may be employed. This involves the use of a dosage of 50-75 kBq / kg of body weight on a dosing schedule of every 4-6 weeks. A flat dosing may also be employed where the dose does not depend on the body weight of the subject. Such dosing improve the benefit / risk profile with fewer adverse events and less discontinuations, dosing interruptions and reductions in dose. Of particular importance is a reduction in salivary gland toxicity and xerostomia.

The invention relates to a construction method of an experimental autoimmune prostatitis rat model. The construction method comprises the following steps: S1, preparing a prostate specific antigen mixture; s2, selecting male SD rats as laboratory rats, and dividing the laboratory rats into a normal saline control group, a low-dose model group and a high-dose model group; s3, continuously injecting for 7 days, allowing the normal saline control group to accept injection of 0.2 ml of normal saline every day, allowing the low-dose model group to accept injection of 0.1 ml of prostate specific antigen mixture every day, and allowing the high-dose model group to accept injection of 0.2 ml of prostate specific antigen mixture every day; and S4, continuously feeding all groups of experimental mice to the 28th day, inducing the experimental mice in the low-dose model group and the high-dose model group by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and obtaining the experimental autoimmune prostatitis rat model. The use of animals can be reduced, the cost is reduced, and the modeling efficiency and stability can be improved.

The invention discloses a low-dose CT denoising method and device based on wavelet transform and a state space model, and relates to the technical field of medical image processing. The method comprises the following steps: acquiring a low-dose CT image and a corresponding full-dose CT image, and generating a data set; dividing the data set into a training set and a test set according to a preset proportion; constructing and training a CT denoising network, taking the training set as an input parameter, taking the predicted image as an output parameter, and taking the minimum error absolute value of the full-dose CT image and the predicted image as a loss function; and inputting the test set into the trained CT denoising network in the step S3 to obtain a prediction image. According to the low-dose CT denoising method, global dependence can be efficiently established, and details can be accurately reserved.

This invention discloses an intelligent adaptive dose verification calculation method and system. The intelligent adaptive dose verification calculation method includes: obtaining preliminary dose distribution data for a patient based on a deep learning-based dose prediction model; dynamically assigning variance reduction parameters to particles in a Monte Carlo simulation based on the high and low dose distribution information in the preliminary dose distribution data, wherein the variance reduction parameters include simulation weights, with simulation weights assigned to particles predicted to be in high-dose regions being less than those assigned to particles predicted to be in low-dose regions; and using a Monte Carlo dose calculation engine, simulating the planned beam based on the dynamically assigned variance reduction parameters to obtain high-precision verification dose distribution data. This invention's intelligent adaptive dose verification calculation method ensures the physical authenticity of the final verification dose distribution and the credibility of the "gold standard."

The application discloses application of a low-dose anti-PD-1 antibody in a limited course of treatment in treatment of hepatitis B. Anti-PD-1 antibody treatment is carried out on a chronic hepatitis B patient receiving nucleoside analogue or nucleotide analogue treatment, 100 mg is injected intravenously each time, once every three weeks, and the course of treatment is ended after 12 weeks or 24 weeks. The application blocks the combination of the PD-1 receptor highly expressed on the surface of T cells of the CHB patient with a ligand by blocking the CHB patient T cell surface high expression of the PD-1 receptor, thereby reversing the T cell exhaustion state, enhancing the HBV specific T cell immune response, and promoting HBsAg clearance. The application uses a limited course of treatment and a low-dose alpha PD-1 to enhance the HBV specific T cell immune response of the patient and promote the clearance of HBsAg while ensuring good safety. Compared with the traditional 48-week Peg-IFN alpha or several years or even decades of NAs treatment of the CHB patient, the 12-week or 24-week course of alpha PD-1 is shorter and has a smaller economic burden on the patient.

Provided herein is a method of adoptive cell therapy. The method includes administering to a subject a low dose lymphodepletion regimen and administering to the subject a population of tumor infiltrating lymphocytes. Also provided herein is a method of treating cancer in a subject by administering to the subject a low dose lymphodepletion regimen and administering to the subject a population of tumor infiltrating lymphocytes.

The invention provides a cobalt-based nano-motor, a preparation method thereof and application of the cobalt-based nano-motor in preparation of space distribution heterogeneity drugs for radiotherapy injury, and belongs to the technical field of nano-drugs. The cobalt-based nano motor constructed by the invention can amplify the killing effect of ROS on tumor cells under low-dose X-ray irradiation, and obviously enhance the tumor radiotherapy effect. Besides, the cobalt-based nano motor contains ammonium bicarbonate, so that the cobalt-based nano motor can respond to a tumor acidic microenvironment, release carbon dioxide in the tumor acidic microenvironment, push the carbon dioxide to go deep into tumor tissues and accumulate in tumors, consume antioxidant glutathione in tumor cells through a catalytic treatment effect, and amplify ROS damage. According to the invention, the cobalt-based nano-motor is preliminarily proved to realize non-uniform radiodynamic therapy by virtue of the excellent penetrating power of the cobalt-based nano-motor in tumor tissues, and achieve the effect of spatial distribution heterogeneity of radiotherapy injury, so that the immune response is activated, and the effect of improving the tumor radiotherapy curative effect is realized.

The application relates to the technical field of scintillator screen and discloses a flexible scintillator screen with low-dose X-ray imaging performance and a process thereof, which comprises a high-efficiency 2D perovskite scintillator material layer, a transparent conductive polymer layer and a flexible substrate, the high-efficiency 2D perovskite scintillator material is Cs2AgBiBr6, the flexible substrate is a polyimide film or a PET film, the transparent conductive polymer layer is arranged on one side or both sides of the high-efficiency 2D perovskite scintillator material layer, and the transparent conductive polymer layer material is PEDOT:PSS or PANI. The low-dose X-ray imaging performance is improved through the micro-nano structure and the gradient structure; the micro-nano structure can control the propagation and emission direction of the scintillator light emission, improve the light extraction efficiency or the detection sensitivity; the gradient structure matches the intensity difference of the X-ray penetrating object, avoids signal saturation or loss, and optimizes the light collection efficiency and the imaging quality.

The invention belongs to the technical field of biological medicines, and relates to application of cisplatin combined with triazole C in preparation of a medicine for treating diffuse large B-cell lymphoma. The research of the invention shows that cis-platinum (especially low-dose cis-platinum) can effectively inhibit DLBCL dispersion by inhibiting ATOX1 LLPS; the triazolin C can destroy a copper steady state by inhibiting lipid droplet synthesis, so that copper in cells is overloaded, and copper death is induced; animal experiments show that after the cisplatin (especially low dosage) and the triazole C are combined for use, the progress and the dissemination of the DLBCL can be remarkably inhibited, so that the lifetime is remarkably prolonged, and the purpose of treating the DLBCL is achieved.

This document provides an apparatus for delivering solid and gaseous carbon dioxide, comprising: (i) a liquid carbon dioxide source including a tank containing liquid carbon dioxide; (ii) a first conduit including a proximal end operatively connected to the liquid carbon dioxide source and a distal end operatively connected to an orifice; (iii) a second conduit operatively connected to the orifice to guide a mixture of gaseous and solid carbon dioxide to a desired destination; and (iv) a third conduit operatively connected to the second conduit, wherein the third conduit includes a portion configured to sufficiently slow the flow of solid carbon dioxide through that portion of the third conduit to cause the solid carbon dioxide to agglomerate before exiting the third conduit through an opening. The apparatus is capable of delivering a precise dose of carbon dioxide at a desired solid-to-gas ratio under low-dose conditions and / or intermittent conditions.

The application relates to a method for constructing an experimental autoimmune prostatitis rat model, which comprises the following steps: S1, preparing a prostate specific antigen mixture; S2, selecting male SD rats as experimental rats and dividing the rats into a physiological saline control group, a low-dose model group and a high-dose model group; S3, continuously injecting for 7 days, wherein the physiological saline control group receives 0.2ml of physiological saline injection every day, the low-dose model group receives 0.1ml of the prostate specific antigen mixture injection every day, and the high-dose model group receives 0.2ml of the prostate specific antigen mixture injection every day; and S4, continuing to feed all the experimental rats in the groups until the 28th day, wherein the experimental rats in the low-dose model group and the high-dose model group are induced by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and an experimental autoimmune prostatitis rat model is obtained. The method can not only reduce the use of animals and the cost, but also improve the modeling efficiency and stability.

Methods of using low dose naltrexone to treat chronic pain in a patient. The methods of using low dose naltrexone to treat chronic pain generally includes administering to the patient a first amount of naltrexone in an immediate-release agent and a second amount of naltrexone in a modified-release agent.

The invention described herein provides methods and reagents to treat muscular dystrophy (such as DMD), using an nNOS-binding domain containing microdystrophin coding sequence delivered by a modified AAV capsid (SLB-101) having superior expression profile in target tissues.

The invention discloses a product irradiation monitoring system and method, and relates to the field of product monitoring. The system comprises an irradiation source device, a product conveying device and an environment monitoring unit, and real-time correction is carried out by constructing a voxelization three-dimensional dose rate grid and combining source activity decay and air density parameters; a path integration algorithm is used to calculate a dynamic accumulated dose according to the instantaneous position and speed of the product, and the transmission frequency is adjusted in a closed-loop manner. The system is also integrated with a non-contact dose verification unit based on passive RFID for model calibration, and an excessive radiation estimation and automatic source reduction protection mechanism for a card chain fault. According to the invention, through multi-dimensional environment perception and dynamic integral calculation, the problems of low dose control precision and lack of real-time feedback in traditional irradiation processing are effectively solved, and the stability and safety of product irradiation quality are ensured.

The utility model relates to the technical field of medical instruments, in particular to a blister box which comprises a box body, and a main clamping groove used for loading a main product, an auxiliary clamping groove used for loading an auxiliary product of the main product, an auxiliary clamping groove used for loading a drying agent and an oxygen absorbent and an airflow groove used for air circulation in the box body are formed in the box body. The main clamping groove, the auxiliary clamping groove and the auxiliary clamping groove are communicated through the airflow grooves to form a coherent airflow channel, and the airflow channel is provided with an air inlet and an air outlet which penetrate through the box body. Integrated combined packaging and sterilization of a main product and an auxiliary product can be achieved, low-dose irradiation sterilization is met, the main clamping groove, the auxiliary clamping groove and the auxiliary clamping groove are communicated with one another through the airflow groove formed in the box body to form a coherent airflow channel, gas in the box body can be effectively replaced, water and oxygen retention in the box body is avoided, and the packaging effect is good. The influence of water oxygen on the service life of a main product is reduced.

Medical devices capable of filling liquid into a syringe barrel while evacuating any air from the syringe are described. An exemplary medical device includes a syringe barrel having a tapered sidewall portion for permitting air to vent from the chamber and preventing liquid from exiting the chamber, a plunger rod, and stopper. Another exemplary medical device includes a syringe barrel having a plurality of air venting grooves associated with the sidewall of the barrel, a plunger rod and stopper. Also described is a medical device including a syringe barrel, plunger rod and stopper having a porous plug. Described is a medical device including a syringe barrel having a plurality of air venting grooves associated with the sidewall of the barrel and a porous membrane disposed over the air venting grooves, a plunger rod and stopper. Methods for filling a syringe barrel with a liquid are also provided.

The invention discloses a low-dose interferon composition for relieving adverse reaction and application thereof, the low-dose interferon composition is used for treating or preventing diseases caused by virus infection of cats, the composition comprises low-dose alpha-2b type interferon with the concentration of 160 IU / ml to 100,000 IU / ml, and the composition is applied to a required individual in an oral preparation manner.